详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Stroke Risk Status, Anticoagulation Treatment, and Quality-of-Life in Chinese Patients with Atrial Fibrillation: China Registry of Atrial Fibrillation (CRAF)

文献详情

资源类型：

收录情况： ◇ SCIE

作者：

机构： [1]China-Japan Friendship Hospital, Beijing, China [2]Emergency and Intensive Care Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China [3]Cardiology Division, Beijing An Zhen Hospital, Capital Medical University, Beijing, China [4]Department of Cardiology, Shanghai First People’s Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200080, China [5]Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, 116000, China [6]Department of Cardiology, Peking University People’s Hospital, Beijing, 100044, China

出处：

DOI：

ISSN：

摘要：

Objective. To investigate the contemporary status of stroke risk profile, antithrombotic treatment, and quality-of-life (QoL) of patients with all types of atrial fibrillation (AF) in China. Design. This is a multicenter, cross-sectional study. Setting. Tertiary (80%) and Tier 2 hospitals (20%) were identified in different economic regions (Northeast, East, West, and Middle) by using a simple random sampling. Participants. A total of 3562 (85.6%) patients with nonvalvular atrial fibrillation (NVAF) and 599 (14.4%) with rheumatic valvular atrial fibrillation (VAF) were consecutively enrolled from 111 hospitals from July 2012 to December 2012. Data Collection. Patient information was collected and QoL was assessed using Short-Form 36 Health Survey (SF-36) questionnaire. Primary and Secondary Outcome Measures. The risk of stroke was assessed using the CHADS2 and CHA2DS2-VASc. QoL was assessed using Medical Outcomes Study SF-36 questionnaire. Results. Overall, 31.7% of the patients received anticoagulant treatment and 61.2% received antiplatelet treatment. The rate of anticoagulant treatment was higher in patients with VAF than in those with NVAF. The anticoagulant use was the lowest in Northeast and the highest in Middle regions. Independent risk factors associated with underuse of anticoagulants for NVAF were age, systolic blood pressure (SBP), non-Middle regions, nontertiary hospitals, and new-onset or paroxysmal AF. For VAF patients, the independent factors were age, paroxysmal AF, treatment in Tier 2 hospitals, SBP, diastolic blood pressure, history of coronary artery disease, and nonreceipt of antiarrhythmic therapy. Patients receiving anticoagulants fared significantly better in some QoL domains than those who received no antithrombotic therapy. Conclusions. These findings suggest that antiplatelet treatment is overused and anticoagulant treatment is underused both in Chinese patients with VAF and NVAF, even though usage of anticoagulants is associated with better QoL. Risk factors with underuse of anticoagulants were not identical in patients with NVAF and VAF. © 2019 Yihong Sun et al.

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 3 区医学

小类 | 3 区药学 4 区心脏和心血管系统

最新[2023]版：

大类 | 4 区医学

小类 | 3 区药学 4 区心脏和心血管系统

JCR分区：

出版当年[2017]版：

Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Q3 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Q2 PHARMACOLOGY & PHARMACY

影响因子： 3.4 最新[2023版] 3.2 最新五年平均 2.245 出版当年[2017版] 2.706 出版当年五年平均 2.478 出版前一年[2016版] 2.315 出版后一年[2018版]

第一作者：

第一作者机构： [1]China-Japan Friendship Hospital, Beijing, China

通讯作者：

通讯机构： [6]Department of Cardiology, Peking University People’s Hospital, Beijing, 100044, China

推荐引用方式(GB/T 7714)：

APA：

MLA：